Sarepta Therapeutics Inc. (SRPT) Receives Outperform Rating from Wedbush
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating restated by analysts at Wedbush in a report issued on Monday. They currently have a $72.00 price target on the stock, up from their prior price target of $66.00. Wedbush’s price objective would suggest a potential upside of 24.37% from the stock’s current price.
Several other equities research analysts also recently issued reports on SRPT. Vetr upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “sell” rating and set a $17.28 target price for the company in a research note on Tuesday, June 14th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, June 21st. Jefferies Group reiterated an “underperform” rating and issued a $7.00 target price on shares of Sarepta Therapeutics in a research note on Saturday, June 25th. William Blair reiterated a “market perform” rating on shares of Sarepta Therapeutics in a research note on Monday, June 27th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $23.00 target price on shares of Sarepta Therapeutics in a research note on Monday, June 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $58.44.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 0.71% during trading on Monday, reaching $57.48. The company had a trading volume of 1,455,289 shares. The company’s market cap is $2.75 billion. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73. The firm has a 50-day moving average of $40.98 and a 200-day moving average of $25.39.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/sarepta-therapeutics-inc-srpt-receives-outperform-rating-from-wedbush-3.html
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the business earned ($0.87) earnings per share. On average, equities research analysts anticipate that Sarepta Therapeutics will post ($4.23) EPS for the current year.
In other news, CEO Edward M. Md Kaye sold 40,179 shares of Sarepta Therapeutics stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total transaction of $2,410,740.00. Following the transaction, the chief executive officer now directly owns 117,162 shares of the company’s stock, valued at $7,029,720. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP David T. Howton sold 7,000 shares of Sarepta Therapeutics stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total transaction of $420,000.00. Following the transaction, the senior vice president now directly owns 28,453 shares in the company, valued at $1,707,180. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. BlackRock Fund Advisors boosted its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares in the last quarter. State Street Corp boosted its position in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock worth $48,168,000 after buying an additional 865,658 shares in the last quarter. Commonwealth Equity Services Inc purchased a new position in shares of Sarepta Therapeutics during the second quarter worth $302,000. National Planning Corp boosted its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in shares of Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares in the last quarter. 65.29% of the stock is currently owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.